BridgeMD
Compares treatment options for Nasopharyngeal Cancinoma (NPC)
Official title Phase 3 Trial Comparing IMRT or IMPT Plus CIRT for Patients With NPC
ClinicalTrials.gov ID: NCT06846450
What this study is testing
What is Concurrent chemotherapy?
Concurrent chemotherapy is an investigational medicine, given as an once-weekly, being studied as a potential treatment for nasopharyngeal cancinoma (npc).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this phase 3 non-inferiority trial is to compare the efficacy and toxicity of proton or photon radiation therapy plus carbon ion radiation therapy for newly diagnosed nasopharyngeal carcinoma. The main question it aims to answer is that if proton radiation therapy plus carbon ion radiation therapy is non-inferior to photon radiation therapy plus carbon ion radiation therapy in terms of therapeutic efficacy.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Willingness to sign the written informed consent.
- Pathologically confirmed Nasopharyngeal carcinoma.
- Patients with any stage of disease except distant metastasis.
- Age: ≥ 18 and ≤ 70 years old.
- Eastern Cooperative Oncology Group score: 0-1.
You likely can't join if
- Presence of distant metastasis.
- Previous radiotherapy to head and neck region.
- Previous surgery (except for biopsy) for the primary lesion or cervical lymph nodes.
- History of malignant tumor within the past 5 years.
- Presence of multiple primary tumors.
- Presence of diseases that may interfere with the evaluation of study endpoints.
See the full eligibility criteria
- Willingness to sign the written informed consent.
- Pathologically confirmed Nasopharyngeal carcinoma.
- Patients with any stage of disease except distant metastasis.
- Age: ≥ 18 and ≤ 70 years old.
- Eastern Cooperative Oncology Group score: 0-1.
- Adequate laboratory test results.
- Willingness to accept adequate contraception.
- Presence of distant metastasis.
- Previous radiotherapy to head and neck region.
- Previous surgery (except for biopsy) for the primary lesion or cervical lymph nodes.
- History of malignant tumor within the past 5 years.
- Presence of multiple primary tumors.
- Presence of diseases that may interfere with the evaluation of study endpoints.
- Presence of severe major organ dysfunction.
- Mental illness that may affect the understanding of informed consent.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.